Annovis Bio (NYSE:ANVS – Get Free Report) and Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Institutional and Insider Ownership
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 32.3% of Annovis Bio shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Annovis Bio and Eterna Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annovis Bio | N/A | N/A | -$56.20 million | ($2.56) | -0.48 |
| Eterna Therapeutics | $582,000.00 | 16.61 | -$21.67 million | ($8.31) | -0.02 |
Analyst Recommendations
This is a summary of current recommendations and price targets for Annovis Bio and Eterna Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annovis Bio | 0 | 1 | 4 | 1 | 3.00 |
| Eterna Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Annovis Bio currently has a consensus price target of $37.00, indicating a potential upside of 2,883.87%. Given Annovis Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Annovis Bio is more favorable than Eterna Therapeutics.
Risk and Volatility
Annovis Bio has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.79, suggesting that its stock price is 379% more volatile than the S&P 500.
Profitability
This table compares Annovis Bio and Eterna Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annovis Bio | N/A | N/A | -311.00% |
| Eterna Therapeutics | -7,513.88% | N/A | -117.48% |
Summary
Annovis Bio beats Eterna Therapeutics on 7 of the 13 factors compared between the two stocks.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
About Eterna Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
